Vaccine serologic responses among transplant patients associate with COVID-19 1 infection and T peripheral helper cells 2 3 Jacob E. Lemieux<sup>1,2,3#</sup>, Amy Li<sup>4</sup>, Matteo Gentili<sup>3</sup>, Cory A. Perugino<sup>2,5,6</sup>, Zoe F. Weiss<sup>1</sup>, Kathryn 4 Bowman<sup>1</sup>, Pierre Ankomah<sup>1</sup>, Hang Liu <sup>5</sup>, Gregory D. Lewis<sup>2,7</sup>, Natasha Bitar<sup>1</sup>, Taryn Lipiner<sup>1</sup>, 5 Nir Hacohen<sup>1,2,3</sup>, Shiv S. Pillai<sup>2,3,5</sup>, Marcia B. Goldberg<sup>1,2,3,8#</sup> 6 7 <sup>1</sup> Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, 8 Boston, MA 02114, USA; <sup>2</sup> Department of Medicine, Harvard Medical School, Boston, MA 9 02115, USA; <sup>3</sup> The Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, 10 Cambridge, MA 02138, USA; <sup>4</sup> Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; <sup>5</sup> Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; <sup>6</sup> 11 12 Division of Rheumatology Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114; <sup>7</sup> Heart Transplant Program, Department of Medicine, Massachusetts General 13 Hospital, Boston, MA 02114, USA; 8 Department of Microbiology, Harvard Medical School, 14 15 Boston, MA 02115, USA <sup>#</sup> Corresponding authors: Division of Infectious Diseases, Massachusetts General Hospital, 55 16 17 Fruit St., Boston, MA, 02114, USA, jelemieux@partners.org and 18 marcia.goldberg@mgh.harvard.edu 19 Conflict of Interest statement: The authors have declared that no conflict of interest exists. 20 **Abstract** 21 **Background:** Therapeutically immunosuppressed transplant recipients exhibit attenuated 22 responses to COVID-19 vaccines. To better understand the immune alterations that determined

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

poor vaccine response, we correlated quantities of circulating T and B cell subsets at baseline with longitudinal serologic responses to SARS-CoV-2 mRNA vaccination in heart and lung transplant recipients. **Methods:** Samples at baseline and at approximately 8 and 30 days after each vaccine dose for 22 heart and lung transplant recipients with no history of COVID-19, four heart and lung transplant recipients with prior COVID-19 infection, and 12 healthy controls undergoing vaccination were analyzed. Anti-spike protein receptor binding domain (RBD) IgG and pseudovirus neutralization activity were measured. Proportions of B and T cell subsets at baseline were comprehensively quantitated. Results: At 8-30 days post vaccination, healthy controls displayed robust anti-RBD IgG responses, whereas heart and lung transplant recipients showed minimally increased responses. A parallel absence of activity was observed in pseudovirus neutralization. In contrast, three of four (75%) transplant recipients with prior COVID-19 infection displayed robust responses at levels comparable to controls. Baseline levels of activated PD-1<sup>+</sup> HLA-DR<sup>+</sup> CXCR5<sup>-</sup> CD4<sup>+</sup> T cells (also known as T peripheral helper [TPH] cells) and CD4+ T cells strongly predicted the ability to mount a response. Conclusions: Immunosuppressed patients have defective vaccine responses but can be induced to generate neutralizing antibodies after SARS-CoV-2 infection. Strong correlations of vaccine responsiveness with baseline T<sub>PH</sub> and CD4<sup>+</sup> T cell numbers highlights a role for T helper activity in B cell differentiation into antibody secreting cells during vaccine response.

## Introduction

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

For immunocompetent individuals, SARS-CoV-2 vaccination is a highly effective preventative approach for protection from COVID-19 (1-3). However, because Phase 3 trials excluded immunosuppressed individuals, the approach to and determinants of induction of protective immunity against SARS-CoV-2 among transplant recipients and other severely immunosuppressed individuals is less clear. Heart and lung transplant recipients require a higher degree of immunosuppression to prevent graft rejection than other solid organ transplant recipients. Their regimens typically include a calcineurin inhibitor (tacrolimus more often than cyclosporine), a DNA synthesis inhibitor (mycophenolate more often than azathioprine) and/or a mammalian target of rapamycin (mTOR) inhibitor (sirolimus), and low-dose glucocorticoids. Whereas both DNA synthesis inhibitors and calcineurin inhibitors block T cell expansion, tacrolimus may particularly impact follicular helper T cells (4), which are critical for the affinity maturation and isotype switching of an effective antibody response. Loss of mTOR activity not only blunts T and B cell proliferation, but also impairs the development of CD8+ T cell memory (5), skews helper T cell differentiation toward regulatory T cells (6, 7), and disrupts B cell progression through germinal center reactions, including class switching and somatic hypermutation (8–10). Furthermore, glucocorticoids interfere with activities of virtually all immune cells. Previous to COVID-19, several reports demonstrated attenuated or delayed serologic responses to various vaccines among severely immunosuppressed hosts (11–15). Vaccine efficacy in this patient population may depend in part on the nature of the vaccine and is sometimes improved by booster vaccination (16). Published data on antibody responses to SARS-CoV-2 mRNA

vaccination in transplant recipients indicate major impairments in vaccine-induced humoral and cellular immunity (16–25). Whether transplant recipients are uniquely vulnerable to more transmissible viral strains with spike protein variants, which are rising in prevalence globally, remains unclear. Hence, there is an urgency to determine why transplant recipients do not respond to standard SARS-CoV-2 mRNA vaccinations and to identify solutions to protect this vulnerable patient population.

Here, we quantitatively assessed the antibody response to SARS-CoV-2 vaccination among heart and lung transplant recipients, including neutralization activity to emerging variants of concern, extending recent findings from other groups (17, 22–25). Further, to identify cellular correlates of adaptive immune determinants of vaccine responsiveness, we quantified subsets of CD4<sup>+</sup> T helper cells, CD8+ T cells, and B cells at baseline and correlated these with levels of serum IgG.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

**Results** 

Serum IgG responses among vaccinated heart and lung transplant recipients were markedly diminished compared to those of healthy controls. Among vaccinated heart and lung transplant recipients with no evidence of prior or intercurrent (between vaccine doses) COVID-19 infection (N=16 heart and N=6 lung transplant recipients), levels of IgG recognizing the SARS-CoV-2 RBD were markedly lower than those of healthy controls (Fig. 1). At 8 and 30 days after the second vaccine dose, IgG anti-RBD levels were 22-fold lower ( $p = 2.9 \times 10^{-7}$ ; Wilcoxon rank-sum test) and 20-fold lower ( $p = 6.7 \times 10^{-4}$ ; Wilcoxon rank-sum test), respectively, among transplant recipients compared to those of healthy controls. Neutralization activity of plasma from vaccinated heart and lung transplant recipients were markedly diminished compared to that of healthy controls. Neutralization activity to SARS-CoV-2 pseudovirus among vaccinated heart and lung transplant recipients largely paralleled IgG levels. At 8 days after the second vaccine dose, mean neutralizing antibody activity of transplant recipients was 12.2-fold less than that of healthy controls ( $p = 2.9 \times 10^{-7}$ , Wilcoxon rank-sum test, Fig. 2A), and at 30 days after the second vaccine dose, neutralizing antibody activity of transplant recipients was 12.0-fold less than that of healthy controls (Wilcoxon rank-sum test, p = 0.001, Fig. 2B). Similar to previously published results (26–31), among healthy controls, neutralizing activity to variant pseudoviruses containing the E484K/N501Y/D614G mutations present in the beta (B.1.351) and gamma (P.1) variants (originally identified in South Africa and Brazil, respectively) were reduced (Fig. S1C). Among control patients at later time points (1d pre dose 2 through 68d post dose 2), neutralization against E484K/N501Y/D614G pseudovirus was 22%

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

lower than against D614G pseudovirus ( $p = 6.6 \times 10^{-6}$ , paired Wilcoxon test) and 24% lower than against N501Y/D614G pseudovirus (p =  $3.8 \times 10^{-5}$ , paired Wilcoxon test) (Fig. S1C), representative of the alpha (B.1.1.7) variant originally identified in the United Kingdom; the difference in neutralization between D614G and N501Y/D614G pseudoviruses was not significant. Among both transplant recipients and healthy controls, neutralizing antibody titers correlated strongly with levels of anti-RBD IgG, although this correlation decreased with additional variant mutations in the RBD (Fig. S2). Time course of response. The differences in responses between the transplant recipients and the healthy controls were evident as early as 20 days after the first vaccine dose (1 day prior to the second vaccine dose), when all but two healthy controls yet none of the transplant recipients displayed increases in IgG above background (Figs. 3, S3, and S4). Following the second dose of vaccine, IgG levels and neutralization activity progressively increased in two COVID-19uninfected transplant recipients and all of the controls (Figs. 3 and S4). Increases in neutralization activity correlated highly with the increases in IgG levels (for D614G pseudovirus and IgG levels, R=0.88, Fig. S2A). The increases in these two transplant recipients were delayed compared to the controls; whether they will continue to increase at later times will be determined with additional follow-up. Consistent with prior publications in which lower immunosuppression is associated with improved serologic responses (17, 22–24), these two transplant recipients were on levels of immunosuppression at the lower end of our cohort; one was not on a DNA synthesis inhibitor, and both were on only 5 mg daily of prednisone. Prior or intercurrent infection with COVID-19 is associated with strong serological responses and neutralizing activity. Three transplant recipients had COVID-19 prior to vaccination, and one had COVID-19 between the first and second vaccine dose. Three of these

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

four transplant recipients displayed IgG levels and neutralization activity were comparable to those of healthy controls (Fig. 3B, 3D). For the three of these individuals who displayed elevated IgG levels and neutralization activity, vaccination per se was associated with a boost in IgG levels, and for one, a boost in neutralization activity; for the other two who responded, it was not possible to determine whether neutralization activity was boosted, as it was >95% at baseline (Fig. 3D). The proportion of subjects who responded to vaccination was significantly different among transplant patients with prior COVID-19 (p = 0.018, Fisher's exact test). Proximity to transplantation and the higher doses of immunosuppressive medications generally administered around transplantation may have contributed to the absence of response in the COVID-19infected non-responder, as this individual developed infection <1 year after transplantation, whereas the other three COVID-19-infected transplant recipients developed infection 2-5 years (N=2) and >15 years (N=1) after transplantation. No differences in immunosuppressive regimens at the time of vaccination or the severity of COVID-19 infection between the one COVID-19infected non-responder and the three COVID-19-infected responders were identified. Nor were any differences in immunosuppressive regimens identified between the COVID-19-infected and uninfected transplant recipients. Peripheral blood immune cell populations at early time points and cellular predictors of antibody response. To identify differences that may underlie the differential response to vaccination, we performed high-dimensional flow cytometry on baseline samples and quantified peripheral blood immune cell subsets at early time points. We found significant differences in peripheral blood immune cells including CD3+ lymphocytes (p = 0.04, wilcoxon test), CD4+ T lymphocytes (p = 0.002), T peripheral helper ( $T_{PH}$ ) cells, Tregs (p = 0.02) and DR+ T cells (p = 0.0059). The relative proportion of  $T_{PH}/CD4+ (p = 0.0093)$ , DR+/Tregs (p = 0.00031), and

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

DR+/CD4+ (p = 0.04) were also decreased among transplant patients as compared to controls (Fig. 4A and S5A). In contrast, we did not observe significant differences in CD8+ T cells and CD19+ B cell populations. To identify potential cellular predictors of the antibody response to vaccination, we computed correlation statistics between baseline flow cytometry and antibody response at 8 days post second dose (Fig. S5B). Most strongly correlated with antibody response was the absolute number of T peripheral helper (T<sub>PH</sub>) cells (Pearson correlation coefficient, r = 0.72, p = 0.0036), and this relationship held for the proportion of  $T_{PH}$  cells among total CD4<sup>+</sup> cells (r = 0.62, p = 0.02).  $T_{PH}$  cells are PD-1<sup>+</sup> CXCR5<sup>-</sup> HLA-DR<sup>+</sup> CD4<sup>+</sup> T cells and represent a subset of CD4<sup>+</sup> T cells that have been shown to drive B cell differentiation into antibody secreting cells (32). A substantial yet weaker relationship was present between day 8 IgG levels and HLA DR+ CD4+ T cells (Fig. 4B). We observed no significant correlations between serologic responses and the baseline proportions of total effector-memory CD4<sup>+</sup> T cells, regulatory T cells, HLA-DR<sup>+</sup> (activated) regulatory T cells, naïve CD4<sup>+</sup> T cells, or circulating T follicular helper T cells among total CD4<sup>+</sup> T cells, effector-memory CD8<sup>+</sup> T cells, CD8<sup>+</sup> cytotoxic T cells, or CD8<sup>+</sup> naïve T cells among total CD8<sup>+</sup> T cells, naïve, unswitched memory, switched memory, or double-negative (IgD-CD27-) B cells among total CD19+ B cells.

### Discussion

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

In this study, we provide the first in-depth longitudinal comparison of immune responses to SARS-CoV-2 vaccination in heart and lung transplant recipients to responses to vaccination of healthy controls and of heart and lung transplant recipients with prior COVID-19 infection. In addition, we provide the first correlation of these responses to quantitative analyses of baseline T and B cell subsets. Consistent with findings of other investigators (16–25), we show that COVID-19-naive heart and lung transplant recipients have a profound reduction in neutralizing antibodies against SARS-CoV-2 spike protein and receptor binding domain (RBD)-specific immunoglobulin levels after both prime and boost vaccine doses. However, transplant recipients who had COVID-19 infection prior to vaccination displayed neutralizing antibodies to SARS-CoV-2 at baseline that increased following vaccination. Taken together, the disparate humoral immune response to SARS-CoV-2 vaccine as compared to natural infection in heart and lung transplant patients is suggestive of a failure of vaccines to induce immunologic priming in highly immunosuppressed patients, and points to the need for alternate immunization regimens for these populations. The vast majority of participants received the two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccine (88%), with only two heart and lung transplant recipients (7.7%) receiving the two-dose mRNA-1273 (Moderna) vaccine and only one (3.8%) receiving the single-dose Ad26.COV2.S (Janssen) adenovirus-based vaccine; as a result, we were unable to assess vaccine-related outcomes and our outcomes in aggregate are largely reflective of responses to the Pfizer vaccine. Our data are consistent with recent studies showing response rates of 0-49% in heart and lung transplant recipients receiving the BNT162b2 mRNA vaccine (22, 24, 33, 34). These studies

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

provided evidence of lower anti-spike IgG levels in transplant recipients; we show that this is corroborated by lower neutralizing antibody titers as well. These studies also showed an association between poor response and the use of various immunosuppressive regimens, particularly those including DNA synthesis and calcineurin inhibitors. Compared with our findings, the higher response rates (up to 49%) observed in heart and lung transplant recipients in three of these studies (22, 24, 33) may reflect lower proportions of patients on combined calcineurin and DNA synthesis inhibition as well as maintenance steroids, whereas the vast majority of transplant recipients described in Havlin et al. (34) and in our cohort, who had a uniform lack of response to vaccine, are maintained on three-drug therapy. The presence of robust neutralizing antibody titers in 3 of the 4 transplant recipients with prior COVID-19 infection in our study suggests that heavily immunosuppressed patients can nevertheless mount an effective humoral response to natural infection. This is in line with Havlin et al., who found that 85% of lung transplant recipients with SARS-CoV-2 infection developed spike-directed antibodies (34). The higher proportion of T<sub>PH</sub> cells in transplant patients who had prior COVID-19 infection may suggest an expansion in this population due to recent infection, which may in turn facilitate the boost in antibody responses seen in these individuals. A corollary to this is that the uniformly low numbers and proportion of T<sub>PH</sub> cells in uninfected transplant patients may underlie the inability of these individuals to mount spike-specific IgG responses. Our data indicate that mRNA vaccination may be sufficient to boost existing responses, as antispike antibody levels rose post-vaccination in patients with prior COVID-19 infection with similar kinetics to that of healthy controls; however, mRNA vaccination is a far weaker driver of immunologic priming of immune responses than natural infection.

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

The generation of long-lasting humoral immunity depends on a coordinated T and B cell response to antigen. Calcineurin inhibitors have been shown to impact antibody responses by inhibiting T follicular helper (T<sub>FH</sub>) cell differentiation, as well as naive B cell proliferation and plasmablast differentiation (4, 35). In our data, the substantial deficits in total and activated CD4+ in transplant patients at baseline suggests that a failure to mount appropriate T cell help for B cell differentiation results in impaired class switching and memory B cell development. A limitation of our analysis is that pre-vaccine measurements were available only for 3 transplant patients and our "baseline" populations among transplant patients were mixtures of pre-vaccine and 9 days post the first vaccine dose timepoints; however, in the three subjects in whom both pre-vaccine and 9 days post the first vaccine dose timepoints were measured, the responses at the two timepoints were strongly correlated (r = 0.97, >0.99, and >0.99, Fig. S7A), and no trends were observed that would suggest that the observed differences in CD4+ populations between transplant and control were artifactual (Fig. S7B). It remains unclear why natural infection is able to overcome the reduction in baseline CD4+ T cells in many transplant patients (3 of 4 in our study); moreover, in our study, two uninfected transplant patients demonstrated an antibody response, albeit delayed (Fig. 3A and 3C). Delayed responses to SARS-CoV-2 vaccination have also been reported in kidney transplant and chronic dialysis patients (20, 36). The association between IgG responses and T<sub>PH</sub> cells may offer a clue, as these cells have been implicated in extrafollicular B cell differentiation and maintenance (37) and COVID-19 infection induces expansion of T<sub>PH</sub> cells (38) and increases in non-germinal center B cell responses (39). Based on data in humans and monkeys, anti-spike protein IgG and anti-RBD IgG are strong immune correlates of protection to COVID-19 infection (40–42). The weakness of this response

in COVID-19-uninfected vaccinated heart and lung transplant recipients, demonstrated herein and in other studies, raises major concerns that despite vaccination, this population of patients is poorly protected from infection by standard vaccination strategies.

Methods

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

Study participants and clinical and demographic data. Eligible participants were heart and lung transplant recipients followed clinically at our institution and healthy volunteers of similar age and sex distribution. Healthy volunteers were solicited via a publicly accessible institutional website (https://rally.partners.org/) and local newsletters. Candidates for healthy controls were considered eligible if they were 30-80 years old (the same age range as enrolled transplant recipients), were not receiving immunosuppressive medications, and to enable rapid processing of obtained specimens, were living in eastern Massachusetts. All participants were enrolled prior to or up to two weeks after SARS-CoV-2 vaccination. Demographic and clinical data and vaccine type were collected from the electronic medical record and/or study participants. Evidence for prior COVID-19 infection was obtained from the electronic medical record. **Demographics and clinical characterization of participants.** Eighteen heart and eight lung transplant recipients and 12 healthy volunteers receiving SARS-CoV-2 vaccination were enrolled. The age and sex distribution of the transplant and control groups were similar (Table 1). About one half of the heart and lung transplant recipients were 1 to 5 years after transplantation, about 15% of each group were less than one year after transplantation, and onethird of heart and one-quarter of lung transplant recipients were 10 or more years after transplantation (Table 1). For the two-dose vaccines (BNT162b2 and mRNA-1273), the time between vaccine doses reflected each vaccine's prescribed dosing schedule, with the exception of one outlier, whose second dose was delayed due to intercurrent COVID-19 infection (Fig. S6). The vast majority of both heart and lung transplant recipient participants were maintained on a DNA synthesis inhibitor, a calcineurin inhibitor, and prednisone; about a quarter of both heart

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

and lung transplant recipients were also maintained on an mTOR inhibitor (Table 1). Lung transplant recipients were generally maintained on higher doses of prednisone than heart transplant recipients; whereas 75% (6/8) of lung transplant recipients were taking ≥10 mg of prednisone daily, only 6% (1/18) of heart transplant recipients were taking  $\geq 10$  mg daily. No other substantial medication differences between heart transplant and lung transplant participants were observed. Sample collection. Serial blood samples were collected prior to vaccination (N=13), approximately 1 week after the first dose of vaccine (N=18, median 9 days, interquartile range [IQR, 25%-75%] 7-10 days), just prior to the second dose of vaccine (N=30, median 21 days, IQR 19-21 days after first dose), and at approximately 1 week (N=32, median 8 days, IQR 7-10 days), 4 weeks (N=16, median 30 days, IQR 26-34 days), and 8-10 weeks (N=18, median 60 days, IQR 60-69 days) after the second dose of vaccine. Baseline blood samples were defined as a sample collected prior to vaccination (N=12, including 4 transplant recipients and 8 healthy controls) or a blood sample collected approximately 1 week after the first dose of vaccine (N=9, all transplant recipients). Blood collection was either in the institutional Translational and Clinical Research Center or the participant's home by Partners HealthCare at Home. All samples were processed within 4 hours of phlebotomy. Blood samples were centrifuged, and plasma, serum, and PBMCs were isolated and cryopreserved at -180°C. PBMC isolation was performed using BD cell preparation tubes with sodium heparin. Tubes were centrifuged at 1800 x g for 25 minutes. PBMC were washed in HEPES-buffered Hanks saline solution, resuspended in FBS with 10% DMSO, and stored in liquid nitrogen. ELISA and neutralizing antibody assays. Purified SARS-CoV-2 D614G spike protein receptor binding domain (RBD) and whole spike protein were generously provided by Aaron Schmidt.

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

RBD enzyme linked immunosorbent assays (ELISAs) to IgG in participant serum were performed as previously described (43). Measurements were performed in triplicate and the mean of the three replicates was used. Absolute concentrations were determined based on a standard curve fitted in R using the drm package. Inferred values above 1.25mg/uL, twice the value of the most concentrated standard, were replaced with 1.25 mg/uL, a procedure which affected only two samples (9d post dose 1 and 1d pre dose 2) from one individual, a heart transplant recipient with prior COVID-19. Neutralizing activity of plasma against SARS-CoV-2 D614G, N501Y/D614G (representative of RBD of variant B.1.1.7), and E484K/N501Y/D614G (representative of RBD of variants B1.351 and P.1) spike protein pseudoviruses were assayed as previously described (44). pCMV-SARS2SΔC D614G-gp41 was generated by PCR mutagenesis from pCMV-SARS2SΔC-gp41 and Gibson assembly. pCMV-SARS2SΔC N501Y/D614G-gp41 and pCMV-SARS2SΔC E484K/N501Y/D614G-gp41 were obtained by Gibson assembly of the respective gBlocks (IDT) in pCMV-SARS2SΔC D614G-gp41. Flow cytometry. To comprehensively quantitate proportions of B and T cell subsets at baseline, PBMCs were studied using multicolor flow cytometry. Preserved PBMCs were thawed and washed in complete DMEM. Prior to antibody staining, Fc receptors were blocked using Human TruStain FcX (BioLegend, 422302) at a concentration of 1:20 on ice for 15 minutes. Cells were stained sequentially, first for 20 minutes at 37°C, then washed and stained with a second cocktail of antibodies for 30 minutes at 4°C, as previously optimized for each clone. The following antibody panel was used to quantitate B and T cell subsets: anti-human HLA-DR-BUV395 (BD Biosciences, Clone Tu39, 1:400), anti-human CD45RA-BUV563 (BD Biosciences, Clone HI100, 1:600), anti-human CD38-BUV661 (BD Biosciences, Clone HIT2, 1:400), anti-human CCR7-BUV737 (BD Biosciences, Clone 3D12, 1:200), anti-human CD4-BUV805 (BD

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

Biosciences, Clone SK3, 1:100), anti-human CD20-BUV805 (BD Biosciences, Clone 2H7, 1:100), anti-human CD25-BV421 (BioLegend, Clone BC96, 1:25), anti-human CD28-BV480 (BD Biosciences, Clone CD28.2, 1:100), anti-human CD21-BV480 (BD Biosciences, Clone Bly4, 1:100), anti-human CD11c-BV605 (BD Biosciences, Clone B-ly6, 1:100), anti-human CD10 (BD Biosciences, Clone HI10α, 1:25), anti-human PD1-BV711 (BD Biosciences, Clone EH12.1, 1:100), anti-human CD86-BV750 (BD Biosciences, Clone FUN-1, 1:100), anti-human CD8-BV785 (BioLegend, Clone SK1, 1:400), anti-human IgD-BV785 (BioLegend, Clone 1A6-2, 1:100), anti-human CXCR5-A488 (BD Biosciences, Clone RF8B2, 1:100), anti-human CD127-BB700 (BD Biosciences, Clone HIL-7R-M21, 1:50), anti-human CX3CR1-PE (BioLegend, Clone K0124E1, 1:25), anti-human CD27-PE-Dazzle (BioLegend, Clone M-T271, 1:100), antihuman CXCR3-PE-Cy7 (BioLegend, Clone G025H7, 1:50), anti-human CCR6-APC (BioLegend, Clone G034E3, 1:25), anti-human CD19-APC-R700 (BD Biosciences, Clone SJ25C1, 1:25), and anti-human CD3-APC-Vio770 (Milltenyi, Clone BW264/56, 1:200). After staining, cells were washed with 1% BSA in PBS, centrifuged and resuspended in 1% BSA in PBS. Just prior to flow cytometry, dead cells were identified with SYTOX AADvanced Dead Cell Stain (Thermo Fisher Scientific, S10274, 1:1000). Flow cytometry was performed on a BD FACS Symphony cytometer (BD Biosciences, San Jose, CA), and rainbow tracking beads were used to ensure consistent signals between flow cytometry batches. FCS files were analyzed using Flow Jo software (version 10.7.2). The surface markers used to define each cell type are provided in Table 2. A single aliquot of PBMC was thawed and used for flow cytometry. Each aliquot corresponds to cells harvested from a single 8 mL CPT; however, absolute counts may reflect additional noise

incorporated during a single cycle of freezing and thawing. We therefore also report relative counts as a proportion of CD4+, CD8+ and CD19+ cells.

Statistics. Raw data were analyzed with R (45). Pairwise comparisons were performed using a Wilcoxon test. Correlation coefficients and associated p-values were calculated using Pearson's product-moment correlation coefficient. The proportion of subjects who responded to vaccination was calculated by Fisher's exact test. Response to vaccination for each subject was determined by a consistent rise in IgG ELISA over time. Data were displayed using ggplot (46).

Study approval: All study procedures involving human subjects were approved by the Mass General Brigham Human Research Committee, the governing institutional review board at Massachusetts General Hospital. Informed consent was received from participants prior to inclusion in the study, either in writing or by institutional review board-established verbal consent procedures employed during the COVID-19 pandemic. Participants were identified by numbers.

Author contributions:

J.E.L., designed research studies, recruited and consented patients, scheduled patients, conducted experiments, acquired data, analyzed data, wrote manuscript.

A.L., designed research studies, analyzed data, wrote manuscript.

M.G., conducted experiments, acquired data, edited manuscript.

C.A.P., designed research studies, conducted experiments, acquired data, edited manuscript.

Z.W., recruited and consented patients, scheduled patients, acquired data, edited manuscript.

K.B., recruited and consented patients, scheduled patients, edited manuscript.

P.A., recruited and consented patients, scheduled patients, edited manuscript.

H.L., conducted experiments, acquired data.

G.D.L., recruited patients, edited manuscript.

- 347 T.L., recruited and consented patients, scheduled patients.
- N.H., designed research studies.

- 349 S.S.P., designed research studies, analyzed data, edited manuscript.
- 350 M.B.G., designed research studies, recruited and consented patients, scheduled patients, analyzed
- data, wrote manuscript, raised funds to support studies.

Acknowledgments

This work was supported by the American Lung Association COVID-19 Action Initiative
Research Award (to M.B.G.), the Cystic Fibrosis Foundation (to M.B.G.), Doris Duke Charitable
Foundation Physician-Scientist Fellowship (to J.E.L.), a CRI/Bristol Myers Squibb Postdoctoral
Fellowship (CRI 2993) (to M.G.), NIH U19 AI 110495 (to S.S.P.), and NIH UL1 TR 002541-01
(to the Massachusetts General Hospital Translational and Clinical Research Center).

We are grateful to Grace Holland and Kathy Hall of the Massachusetts General Hospital
Translational and Clinical Research Center, Gary Garberg and Jennifer Erickson of Partners
HealthCare at Home, Meaghan Doucette, Aaron Schmidt, and Richelle Charles.

## Figures and legends




Figure 1: Levels of serum IgG to SARS-CoV-2 spike protein RBD among fully vaccinated COVID-19-naive heart and lung transplant recipients. Serum IgG binding to RBD, as measured by ELISA, at 8 days (A) or 30 days (B) after full vaccination, displayed by transplanted organ type. Data for the transplant recipients who had prior COVID-19 infection are excluded. Boxes,  $25^{th}$ ,  $50^{th}$ , and  $75^{th}$  percentile; whiskers, smallest and largest values in dataset up to 1.5x interquartile range. All data points are shown. \*, p < 0.05; \*\*, p < 0.01; \*\*\*\*, p < 0.0001.






Figure 2: Plasma pseudovirus neutralization activity among fully vaccinated COVID-19-naive heart and lung transplant recipients. SARS-CoV-2 neutralization, as measured by pseudovirus neutralization assay, at 8 days (A) or 30 days (B) after full vaccination, displayed by transplanted organ type. Data for the transplant recipients who had prior COVID-19 infection are excluded. Boxes,  $25^{th}$ ,  $50^{th}$ , and  $75^{th}$  percentiles; whiskers, smallest and largest values in dataset up to 1.5x interquartile range. All data points are shown. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.



**Figure 3:** Antibody trajectories over time in individual subjects. (A-B) IgG binding to SARS-CoV-2 spike protein RBD over time, as measured by IgG ELISA, in COVID-19 naive subjects (A) or in subjects with prior COVID-19 infection (B) displayed by transplanted organ type. Neutralization activity over time in COVID-19 naive subjects (C) or in subjects with prior COVID-19 infection (D). All data points are shown.



**Figure 4: Immune cell subsets and cellular correlates of antibody response.** (**A**) Quantification by flow cytometry of peripheral blood cells in COVID-19-naive individuals. (**B**) Correlation between antibody response at day 8 after complete vaccination and baseline levels of DR+ CD4 T peripheral helper (TPH) cells; DR+ CD4 T cells; DR+ CD4 T cells as a proportion of total CD4+ cells at baseline, or TPH cells as a proportion of total CD4+ cells at baseline. Least squares regressions (blue lines). Gray shading, 95% confidence interval (CI). R, correlation coefficient. All data points are shown. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.001; \*\*\*\*\*, p < 0.0001.

Table 1. Demographic and clinical characteristics of cohort

Parameter	Range, description, or normal value	Transplant recipients		Healthy controls	
		Heart (N=18)	Lung (N=8)	All (N=26)	
Age, median yrs. (range)		59	65	61	63
		(41-76)	(35-76)	(35-76)	(37-74)
Female, n (%)		10 (56)	4 (50)	14 (54)	5 (42)
Race / ethnicity, n (%)	Hispanic	2 (11)	0 (0)	2 (8)	0 (0)
	Non-Hispanic	16 (89)	8 (100)	24 (92)	8 (67)
	Unknown	0 (0)	0 (0)	0 (0)	4 (33)
Years since transplant, n (%)	<1	3 (17)	1 (13)	4 (15)	n/a
	(1-5]	8 (44)	4 (50)	12 (46)	n/a
	(5-10]	1 (6)	1 (13)	2 (8)	n/a

	(10-15]	6 (33)	0 (0)	6 (23)	n/a
	≥15	0 (0)	2 (25)	2 (8)	n/a
Prior or concurrent COVID-19 infection, n (%)		2 (11)	2 (25)	4 (15)	0 (0)
Vaccine, n (%)	BNT162b2 (Pfizer-BioNTech)	15 (83)	8 (100)	23 (88)	9 (75)
	mRNA-1273 (Moderna)	2 (11)	0 (0)	2 (8)	3 (25)
	Ad26.COV2.S (Janssen)	1 (6)	0 (0)	1 (4)	0 (0)
Immunosuppressive medication regimen					
DNA synthesis inhibitor <sup>a</sup>		15 (83)	6 (75)	21 (81)	n/a
Calcineurin inhibitor <sup>b</sup>		18 (100)	7 (88)	25 (96)	n/a
mTOR inhibitor <sup>c</sup>		4 (22)	2 (25)	6 (23)	n/a
Prednisone, n (%)	none	2 (11)	0 (0)	2 (8)	n/a

	1-5 mg daily	14 (78)	1 (13)	15 (58)	n/a
	>5 to <10 mg daily	1 (6)	1 (13)	2 (8)	n/a
	≥10 mg daily	1 (6)	6 (75)	7 (27)	n/a

396 Abbreviations: n/a, not applicable. <sup>a</sup> Mycophenolate or azathioprine. <sup>b</sup> Tacrolimus or cyclosporine. <sup>c</sup> Evirolimus or 397 sirolimus.

# Table 2. Surface markers used to define T and B cell subsets

Subset	Defining surface markers
Naive CD4+	CD3+CD4+CD8-CCR7+CD45RA+
Effector-memory CD4+	CD3+CD4+CD8-CCR7-
Regulatory T cells	CD3+CD4+CD8-CCR7-CD127LoCD25Hi
Activated regulatory T cells	CD3+CD4+CD8-CCR7-CD127LoCD25Hi HLA-DR+
Follicular helper T cells	CD3+CD4+CD8-CCR7-CD127+/-CD25+/-CXCR5+
Peripheral helper T cells	CD3+CD4+CD8-CCR7-CD127+/-CD25+/-CXCR5-CX3CR1-CD28+HLA-DR+PD1+
Naïve CD8+	CD3+CD4-CD8+CCR7+CD45RA+
Effector-memory CD8+	CD3+CD4-CD8+CCR7-
CD8+ cytotoxic T cells	CD3+CD4-CD8+CCR7-CX3CR1+CD28-
Naïve B cells	CD3-CD19+IgD+CD27-
Unswitched memory B cells	CD3-CD19+IgD+CD27+

Switched memory B cells	CD3-CD19+IgD-CD27+
Double negative B cells	CD3-CD19+IgD-CD27-

### References

- 1. Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J.
- 402 *Med.* 2020;383(27):2603–2615.
- 2. Baden LR et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J.
- 404 *Med.* 2021;384(5):403–416.
- 3. Sadoff J et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
- 406 N. Engl. J. Med. 2021;384(23):2187–2201.
- 407 4. Wallin EF, Hill DL, Linterman MA, Wood KJ. The Calcineurin Inhibitor Tacrolimus
- 408 Specifically Suppresses Human T Follicular Helper Cells. Front. Immunol. 2018;9:1184.
- 5. Araki K et al. mTOR regulates memory CD8 T-cell differentiation. *Nature*
- 410 2009;460(7251):108–112.
- 411 6. Delgoffe GM et al. The mTOR kinase differentially regulates effector and regulatory T cell
- 412 lineage commitment. *Immunity* 2009;30(6):832–844.
- 7. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. *Nat. Rev.*
- 414 *Immunol.* 2012;12(5):325–338.
- 8. Ersching J et al. Germinal center selection and affinity maturation require dynamic regulation
- 416 of mTORC1 kinase. *Immunity* 2017;46(6):1045–1058.e6.
- 9. Keating R et al. The kinase mTOR modulates the antibody response to provide cross-
- protective immunity to lethal infection with influenza virus. *Nat. Immunol.* 2013;14(12):1266–
- 419 1276.

- 420 10. Raybuck AL et al. B cell-intrinsic mTORC1 promotes germinal center-defining transcription
- 421 factor gene expression, somatic hypermutation, and memory B cell generation in humoral
- 422 immunity. J. Immunol. 2018;200(8):2627–2639.
- 423 11. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after
- 424 solid organ transplantation: a systematic review. *PLoS One* 2013;8(2):e56974.
- 425 12. Langedijk AC et al. Long-term pneumococcal vaccine immunogenicity following allogeneic
- hematopoietic stem cell transplantation. *Vaccine* 2019;37(3):510–515.
- 427 13. van Aalst M et al. The effect of immunosuppressive agents on immunogenicity of
- pneumococcal vaccination: A systematic review and meta-analysis. *Vaccine* 2018;36(39):5832–
- 429 5845.
- 430 14. de Lavallade H et al. Repeated vaccination is required to optimize seroprotection against
- 431 H1N1 in the immunocompromised host. *Haematologica* 2011;96(2):307–314.
- 432 15. Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to hepatitis A
- vaccination in immunocompromised travelers. *J. Infect. Dis.* 2015;212(3):378–385.
- 434 16. Werbel WA et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in
- solid organ transplant recipients: A case series. Ann. Intern. Med. [published online ahead of
- 436 print: June 15, 2021]; doi:10.7326/L21-0282
- 437 17. Boyarsky BJ et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in
- 438 Solid Organ Transplant Recipients. *JAMA* 2021;325(21):2204.
- 18. Benotmane I et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an

- 440 mRNA COVID-19 vaccine in kidney transplant recipients. *bioRxiv* 2021;
- 441 doi:10.1101/2021.03.08.21252741
- 19. Grupper A et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in
- kidney transplant recipients without prior exposure to the virus. Am. J. Transplant [published]
- online ahead of print: April 18, 2021]; doi:10.1111/ajt.16615
- 20. Rincon-Arevalo H et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in
- kidney transplant recipients and dialysis patients. Sci Immunol 2021;6(60).
- 447 doi:10.1126/sciimmunol.abj1031
- 448 21. Sattler A et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2
- 449 (Tozinameran) prime-boost vaccination in kidney transplant recipients. J. Clin. Invest. [published
- 450 online ahead of print: June 8, 2021]; doi:10.1172/JCI150175
- 22. Itzhaki Ben Zadok O et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart
- 452 transplant recipients a prospective cohort study. Eur. J. Heart Fail. [published online ahead of
- 453 print: May 8, 2021]; doi:10.1002/ejhf.2199
- 454 23. Marinaki S et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ
- 455 transplant recipients. American Journal of Transplantation 2021; doi:10.1111/ajt.16607
- 456 24. Peled Y et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and
- antibody response. J. Heart Lung Transplant. [published online ahead of print: April 21, 2021];
- 458 doi:10.1016/j.healun.2021.04.003
- 459 25. Marion O et al. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines
- in Recipients of Solid Organ Transplants. *Ann. Intern. Med.* [published online ahead of print:

- 461 May 25, 2021]; doi:10.7326/M21-1341
- 26. Liu Y et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. *N*.
- 463 Engl. J. Med. [published online ahead of print: May 12, 2021]; doi:10.1056/NEJMc2106083
- 464 27. Liu Y et al. Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med.
- 465 2021;384(15):1466–1468.
- 466 28. Wu K et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N. Engl. J. Med.
- 467 2021;384(15):1468–1470.
- 468 29. Wu K et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from
- 469 global SARS-CoV-2 variants. *bioRxiv* [published online ahead of print: January 25, 2021];
- 470 doi:10.1101/2021.01.25.427948
- 471 30. Wang Z et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
- 472 *Nature* 2021;592(7855):616–622.
- 473 31. Wang P et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*
- 474 2021;593(7857):130–135.
- 475 32. Rao DA et al. AI-19 T peripheral helper cells are expanded in the circulation of active SLE
- patients and correlate with CD21low B cells. *Adaptive Immunity* 2018; doi:10.1136/lupus-2018-
- 477 lsm.19
- 478 33. Shostak Y et al. Early humoral response among lung transplant recipients vaccinated with
- 479 BNT162b2 vaccine. *Lancet Respir Med* 2021;9(6):e52–e53.
- 480 34. Havlin J et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2

- 481 infection in lung transplant recipients. J. Heart Lung Transplant. [published online ahead of
- 482 print: May 20, 2021]; doi:10.1016/j.healun.2021.05.004
- 483 35. De Bruyne R et al. Calcineurin inhibitors dampen humoral immunity by acting directly on
- 484 naive B cells. Clin. Exp. Immunol. 2015;180(3):542–550.
- 485 36. Schrezenmeier EV et al. Immunogenicity of COVID-19 tozinameran vaccination in patients
- on chronic dialysis. *medRxiv* [published online ahead of print:
- 487 2021];https://www.medrxiv.org/content/10.1101/2021.03.31.21254683v1.abstract.cited
- 488 37. Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T follicular helper
- 489 cells in human diseases. *Cell. Mol. Immunol.* 2021;18(3):523–527.
- 490 38. Meckiff BJ et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T
- 491 Cells in COVID-19. *Cell* 2020;183(5):1340–1353.e16.
- 492 39. Kaneko N et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in
- 493 COVID-19. *Cell* 2020;183(1):143–157.e13.
- 494 40. Corbett KS et al. Immune Correlates of Protection by mRNA-1273 Immunization against
- 495 SARS-CoV-2 Infection in Nonhuman Primates. *bioRxiv* [published online ahead of print: April
- 496 23, 2021]; doi:10.1101/2021.04.20.440647
- 497 41. Yu J et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*
- 498 2020;369(6505):806–811.
- 499 42. Mercado NB et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus
- 500 macaques. *Nature* 2020;586(7830):583–588.

43. Iyer AS et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;5(52). doi:10.1126/sciimmunol.abe0367
44. Filbin MR et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med* 2021;2(5):100287.
45. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. *J. Comput. Graph. Stat.* 1996;5(3):299–314.
46. Wickham H et al. Welcome to the Tidyverse. *Journal of Open Source Software* 2019;4(43):1686.